Q-omics provides the consensus-scored CHCHD6 profile across patient tissues and cancer cell-line models. CHCHD6 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, CHCHD6 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, CHCHD6 protein abundance shows 18,576 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KICH, COAD, and GBM as cancer lineages where CHCHD6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHCHD6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHCHD6 survival associations across molecular data types. CHCHD6 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHCHD6 RNA expression–survival associations across cancer types. High CHCHD6 expression shows unfavorable associations in KICH, BRCA and ACC, but favorable associations in LGG, DLBC and READ. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify KICH as the clearest survival context for CHCHD6 RNA expression.
This table summarizes CHCHD6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CHCHD6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHCHD6 shows lower tumor expression in KICH, LUAD and THCA and higher tumor expression in COAD, BLCA and HNSC. The COAD box plot shows higher CHCHD6 RNA expression in tumor versus normal tissue (log2 FC = +1.662, t-test p < 0.001).
This table shows molecular features associated with CHCHD6 in patient tissues and cancer cell lines. In patient samples, CHCHD6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CHCHD6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in CNS and SKIN.
